Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Functional characterization of serine/threonine kinase 19 (STK19) in RAS-mutant cancers

FY 2019-20

Summary
"The Mitogen-Activated Protein Kinase (MAPK) pathway is a critical signaling cascade regulating cellular migration, proliferation and survival following extracellular stimulation. Mutations in RAS genes (H-, K-, N-), which encode key regulators of the MAPK pathway, can lead to uncontrolled signaling and cellular growth. This is a common driving event of many cancers, accounting for 25% of melanoma and 93% of pancreatic cancer. It is imperative to explore new therapies for this subset of cancers, as treatment options for patients are limited. Recently, a novel regulator of NRAS activity was identified: serine-threonine kinase 19 (STK19). An inhibitor for this kinase was also developed, which prevented tumor growth in NRAS-mutant melanoma models. STK19 is a proposed oncogene, due to the presence of a recurrent mutation (STK19 p.D89N) in 5% of melanoma, and was shown to further promote NRAS-mutant tumor growth compared to wild-type STK19. Recent data suggest that the STK19 mutation is in a promoter region regulating the expression of a shorter STK19 isoform, and not a coding mutation. We hypothesize that the shorter STK19 isoform activates H-, K- and NRAS at a conserved residue. We do not believe the STK19 p.D89N protein is expressed; however, we speculate that the promoter mutation may affect STK19 expression and play a role in the development of melanoma. We will validate the presence of the STK19 mutant by measuring transcription and expression levels. We will then test whether the shorter isoform can activate other RAS proteins, performing pull-down assays with Western blotting. Finally, we will determine whether the STK19 inhibitor can target other RAS-mutant cancers, by treating cells harboring different mutations with the inhibitor and measuring cell survival."
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
428861
Name
Heney Kayla
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Functional characterization of serine/threonine kinase 19 (STK19) in RAS-mutant cancers
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chemotherapy; Immunoprecipitation; Mapk/Erk Signaling Pathway; Melanoma; Pancreatic Cancer; Ras-Mutant Cancer; Reverse Transcription-Pcr; Serine-Threonine Kinase 19 (Stk19); Targeted Proteomics; Western Blotting
Abstract
"The Mitogen-Activated Protein Kinase (MAPK) pathway is a critical signaling cascade regulating cellular migration, proliferation and survival following extracellular stimulation. Mutations in <em>RAS</em> genes (H-, K-, N-), which encode key regulators of the MAPK pathway, can lead to uncontrolled signaling and cellular growth. This is a common driving event of many cancers, accounting for 25% of melanoma and 93% of pancreatic cancer. It is imperative to explore new therapies for this subset of cancers, as treatment options for patients are limited. Recently, a novel regulator of NRAS activity was identified: serine-threonine kinase 19 (STK19). An inhibitor for this kinase was also developed, which prevented tumor growth in NRAS-mutant melanoma models. <em>STK19</em> is a proposed oncogene, due to the presence of a recurrent mutation (STK19 p.D89N) in 5% of melanoma, and was shown to further promote NRAS-mutant tumor growth compared to wild-type STK19. Recent data suggest that the <em>STK19</em> mutation is in a promoter region regulating the expression of a shorter STK19 isoform, and not a coding mutation. We hypothesize that the shorter STK19 isoform activates H-, K- and NRAS at a conserved residue. We do not believe the STK19 p.D89N protein is expressed; however, we speculate that the promoter mutation may affect STK19 expression and play a role in the development of melanoma. We will validate the presence of the STK19 mutant by measuring transcription and expression levels. We will then test whether the shorter isoform can activate other RAS proteins, performing pull-down assays with Western blotting. Finally, we will determine whether the STK19 inhibitor can target other RAS-mutant cancers, by treating cells harboring different mutations with the inhibitor and measuring cell survival."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Heney, Kayla
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~